Berberine Protects Cerebral Vessels and Alleviates Diabetic Encephalopathy by Inhibiting the Production of δ-Valerobetaine in the Gut Microbiota

Hyperglycemia in individuals with diabetes causes cognitive impairment, called diabetic encephalopathy (DE). The pathogenesis of DE is closely related to angiopathy, and effective treatment is highly desirable. The botanical agent berberine (BBR) effectively lowers blood glucose in diabetic patients. Here, we show for the first time that BBR significantly improved cognitive function in type 2 diabetic encephalopathy KK-Ay (2DEK) mice. High-resolution imaging via fluorescence micro-optical sectioning tomography (fMOST) revealed that the integrity of brain vessels was improved by BBR treatment. The improvements in average vessel diameter, vessel length, and total vessel volume were significant in the parietal association cortex (PtA), as well as in the CA1 and CA3 regions. A mechanistic study revealed that oral BBR inhibited δ-valerobetaine (δ-VB, a metabolite of the gut microbiota) production in the intestine. As intestinal δ-VB can enter the circulation and activate the Toll-like receptor-4 (TLR-4)/myeloid differentiation factor 88 (MyD88)/nuclear factor kappa B (NF-κB) inflammatory pathway in the epithelial cells of blood vessels through interacting with TLR-4, BBR might reduce the intestinal level of δ-VB to protect the cerebral blood vessels of DE mice and improve their brain function. Fecal microbiota transplantation (FMT) using the gut microbiota from BBR-treated mice confirmed the vital role of the gut microbiota. BBR showed a wide range of effects on the gut flora, also increasing short-chain fatty acid (SCFA) production and decreasing lipopolysaccharide (LPS) levels in the intestine by adjusting the abundance of SCFA- or LPS-producing bacteria. The observed therapeutic efficacy in vivo revealed a synergistic effect of BBR on the gut microbiota. Conclusively, we found an association between the gut microbiota and blood vessels, of which intestinal δ-VB might be a chemical link. Mainly through downregulating δ-VB in the intestine, BBR protected cerebral vessels and alleviated DE.

Authors

Institutions

Publication Details

Journal
Engineering
Published
2025-05-01
DOI
https://doi.org/10.1016/j.eng.2025.04.018
Citations
1
Primary Topic
Berberine and alkaloids research
Type
article
Field-Weighted Citation Impact
1.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Berberine Protects Cerebral Vessels and Alleviates Diabetic Encephalopathy by Inhibiting the Production of δ-Valerobetaine in the Gut Microbiota

Hui Xiang, Zhao Zhai, Hao-Jian Zhang, Xinyu Yang et al.
1 citations
Engineering
Berberine and alkaloids research
1.39
article

Berberine Protects Cerebral Vessels and Alleviates Diabetic Encephalopathy by Inhibiting the Production of δ-Valerobetaine in the Gut Microbiota

Hui Xiang, Zhao Zhai, Hao-Jian Zhang, Xinyu Yang, Hang Yu, Jian‐Dong Jiang, Hengtong Zuo, Jin‐Yue Lu, Shaofeng Xu, Jia-Chun Hu, Yan Wang, Xiaoliang Wang, Jian‐Ye Song, Jie Fu, Zhengwei Zhang, Yi Zhao, Jingyue Wang, Hui Xu, Meng-Liang Ye, Ru Feng, Weiping Wang
article en
1 citations

Abstract

Hyperglycemia in individuals with diabetes causes cognitive impairment, called diabetic encephalopathy (DE). The pathogenesis of DE is closely related to angiopathy, and effective treatment is highly desirable. The botanical agent berberine (BBR) effectively lowers blood glucose in diabetic patients. Here, we show for the first time that BBR significantly improved cognitive function in type 2 diabetic encephalopathy KK-Ay (2DEK) mice. High-resolution imaging via fluorescence micro-optical sectioning tomography (fMOST) revealed that the integrity of brain vessels was improved by BBR treatment. The improvements in average vessel diameter, vessel length, and total vessel volume were significant in the parietal association cortex (PtA), as well as in the CA1 and CA3 regions. A mechanistic study revealed that oral BBR inhibited δ-valerobetaine (δ-VB, a metabolite of the gut microbiota) production in the intestine. As intestinal δ-VB can enter the circulation and activate the Toll-like receptor-4 (TLR-4)/myeloid differentiation factor 88 (MyD88)/nuclear factor kappa B (NF-κB) inflammatory pathway in the epithelial cells of blood vessels through interacting with TLR-4, BBR might reduce the intestinal level of δ-VB to protect the cerebral blood vessels of DE mice and improve their brain function. Fecal microbiota transplantation (FMT) using the gut microbiota from BBR-treated mice confirmed the vital role of the gut microbiota. BBR showed a wide range of effects on the gut flora, also increasing short-chain fatty acid (SCFA) production and decreasing lipopolysaccharide (LPS) levels in the intestine by adjusting the abundance of SCFA- or LPS-producing bacteria. The observed therapeutic efficacy in vivo revealed a synergistic effect of BBR on the gut microbiota. Conclusively, we found an association between the gut microbiota and blood vessels, of which intestinal δ-VB might be a chemical link. Mainly through downregulating δ-VB in the intestine, BBR protected cerebral vessels and alleviated DE.

EngineeringVol. 49
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), National Medical Products Administration (CN)
Zero hunger
Openalex Percentile: Top 21%
Berberine and alkaloids research
1.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.